For patients with advanced or metastatic NSCLC, the National Comprehensive Cancer Network (NCCN) guidelines recommend molecular testing to identify treatable target mutations, including KRAS, EGFR, MET, ALK, and ROS1 (5). Here, ALK is linked to non-small cell lung carcinoma.